Cannabinoid receptor ligand bias: implications in the central nervous system
- PMID: 27835801
- DOI: 10.1016/j.coph.2016.10.005
Cannabinoid receptor ligand bias: implications in the central nervous system
Abstract
The G protein-coupled cannabinoid receptors CB1, CB2, GPR18, and GPR55 regulate neurotransmission, pain, and inflammation and have been intensively investigated as potential drug _targets. Each of these GPCRs is coupled to multiple effector proteins mediating divergent cellular signals. The ligand bias of cannabinoid-_targeted compounds is only beginning to be quantified. Research into cannabinoid bias is now revealing correlations between bias in cell culture and functional outcomes in vivo. We present an example study of cannabinoid bias in the context of Huntington disease. In future, an understanding of cannabinoid receptor structure and quantification of ligand bias will optimize drug selection matched to patient population and disease.
Copyright © 2016 Elsevier Ltd. All rights reserved.
Similar articles
-
RAMP and MRAP accessory proteins have selective effects on expression and signalling of the CB1, CB2, GPR18 and GPR55 cannabinoid receptors.Br J Pharmacol. 2024 Jul;181(14):2212-2231. doi: 10.1111/bph.16095. Epub 2023 Jun 1. Br J Pharmacol. 2024. PMID: 37085333
-
Methods to Quantify Cell Signaling and GPCR Receptor Ligand Bias: Characterization of Drugs that _target the Endocannabinoid Receptors in Huntington's Disease.Methods Mol Biol. 2018;1780:549-571. doi: 10.1007/978-1-4939-7825-0_25. Methods Mol Biol. 2018. PMID: 29856035
-
Protocol to Study β-Arrestin Recruitment by CB1 and CB2 Cannabinoid Receptors.Methods Mol Biol. 2016;1412:103-11. doi: 10.1007/978-1-4939-3539-0_11. Methods Mol Biol. 2016. PMID: 27245896
-
Therapeutic potential of cannabinoid receptor ligands: current status.Methods Find Exp Clin Pharmacol. 2006 Apr;28(3):177-83. doi: 10.1358/mf.2006.28.3.985231. Methods Find Exp Clin Pharmacol. 2006. PMID: 16810344 Review.
-
GPR55 - a putative "type 3" cannabinoid receptor in inflammation.J Basic Clin Physiol Pharmacol. 2016 May 1;27(3):297-302. doi: 10.1515/jbcpp-2015-0080. J Basic Clin Physiol Pharmacol. 2016. PMID: 26669245 Review.
Cited by
-
The Endocannabinoid System and Oligodendrocytes in Health and Disease.Front Neurosci. 2018 Oct 26;12:733. doi: 10.3389/fnins.2018.00733. eCollection 2018. Front Neurosci. 2018. PMID: 30416422 Free PMC article. Review.
-
The Endocannabinoid System and Cannabidiol: Past, Present, and Prospective for Cardiovascular Diseases.Pharmaceuticals (Basel). 2021 Sep 17;14(9):936. doi: 10.3390/ph14090936. Pharmaceuticals (Basel). 2021. PMID: 34577636 Free PMC article. Review.
-
Axonal CB1 Receptors Mediate Inhibitory Bouton Formation via cAMP Increase and PKA.J Neurosci. 2021 Oct 6;41(40):8279-8296. doi: 10.1523/JNEUROSCI.0851-21.2021. Epub 2021 Aug 19. J Neurosci. 2021. PMID: 34413209 Free PMC article.
-
Cannabinoid receptor agonist WIN55212-2 reduces unpredictable mild stress-induced depressive behavior of rats.Ann Transl Med. 2021 Jul;9(14):1170. doi: 10.21037/atm-21-3143. Ann Transl Med. 2021. PMID: 34430611 Free PMC article.
-
Positive Allosteric Modulation of Cannabinoid Receptor Type 1 Suppresses Pathological Pain Without Producing Tolerance or Dependence.Biol Psychiatry. 2018 Nov 15;84(10):722-733. doi: 10.1016/j.biopsych.2017.06.032. Epub 2017 Jul 8. Biol Psychiatry. 2018. PMID: 28823711 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical